Eli Lilly Reports More Positive Data From Combination Antibody Drug In COVID-19 Trial

Eli Lilly and Co (NYSE: LLYhas announced new data from BLAZE-1 Phase 3 study, evaluating the combination of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg in COVID-19 patients.

  • The combination antibody significantly reduced COVID-19 related hospitalizations and deaths (events) in high-risk patients recently diagnosed with COVID-19.
  • These results provide additional efficacy and safety data that support the use of the dose recently granted both FDA Emergency Use Authorization and a positive scientific opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use.
  • There were four events in the bamlanivimab plus etesevimab group and 15 events in the placebo arm, representing an 87% risk reduction.
  • It also demonstrated statistically significant improvements on key secondary endpoints.
  • In February, the U.S. government announced a $210 million purchase agreement to buy 100,000 doses of COVID-19 antibody therapy.
  • Price Action: LLY shares are trading 0.76% higher at $207.1 in premarket trading on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsFDAGeneralCovid-19Phase 3 Study
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!